N-able (Formerly SolarWinds MSP) Announces Partnership With DNSFilter to Help MSPs Protect Customers From Online Security Threats With Advanced DNS Technology

N-able (Formerly SolarWinds MSP) Announces Partnership With DNSFilter to Help MSPs Protect Customers From Online Security Threats With Advanced DNS Technology

DURHAM, N.C.–(BUSINESS WIRE)–N-able (formerly SolarWinds MSP), the purpose-built partner for managed services providers (MSPs), today announced a collaboration with DNSFilter to integrate its cloud-based security solution with N-able N-central® and RMM, providing MSPs with threat protection and content filtering.

The number of phishing attempts continues to rise, with more than 2 million new phishing websites reported in 2020. The new embedded capabilities will help give N-able partners robust protection against these types of threats, including phishing, ransomware, and zero day social engineering attacks.

DNSFilter relies on AI-driven threat categorization that can detect malicious domains up to 80 hours faster than static threat databases. The new capabilities, slated to rollout in N-central this spring with RMM following later in the year, will give MSPs insight into web-based threats from within the N-central or RMM dashboards—while simultaneously providing an additional layer of security, as well as greater network visibility and user-based reporting.

“When computers are outside the borders of our networks, we need a service to help protect access to risky sites and DNS calls. The DNS protection agent protects our endpoints from those malicious DNS calls no matter the location or connection,” explained Jerel Howland, CTO at Mytech Partners. “The partnership between N-able and DNSFilter is an exciting step to securing devices everywhere.”

“MSPs need to ensure they have a reliable web filtering solution, whether users are on or outside of the corporate network; the importance of this has soared rapidly with the rise in remote working and for a lot of organizations, these working conditions are here to stay,” said John Pagliuca, president, N-able. “We know that SMEs are key targets of malicious advertising, phishing, and other harmful sites through DNS-based cyberattacks, and this partnership allows us to provide our partners with a proactive approach to web protection. High volumes of malicious websites are created every day, so the ability to classify and filter sites in real time is a must.”

“Adding an additional layer of protection through DNS filtering can mean the difference between a data breach that costs millions and everyone working safely without interruption,” said Ken Carnesi, CEO, DNSFilter. “We have partnered with N-able as we both strongly believe that having multiple avenues of protection is a necessity for all businesses. After all, there has been a significant rise in targeted attacks by bad actors worldwide. Multilayered security is an integral part of a zero trust approach, and DNSFilter provides an important layer of protection at one of the earliest stages of a possible attack.”

#SWIproducts

About N-able

N-able (formerly SolarWinds MSP) empowers managed services providers (MSPs) to help small and medium enterprises navigate the digital evolution. With a flexible technology platform and powerful integrations, we make it easy for MSPs to monitor, manage, and protect their end customer systems, data, and networks. Our growing portfolio of security, automation, and backup and recovery solutions is built for IT services management professionals. N-able simplifies complex ecosystems and enables customers to solve their most pressing challenges. We provide extensive, proactive support—through enriching partner programs, hands-on training, and growth resources—to help MSPs deliver exceptional value and achieve success at scale. n-able.com

The N-ABLE, N-CENTRAL, and other N-able trademarks and logos are the exclusive property of N-able Solutions ULC and N-able Technologies Ltd. and may be common law marks, are registered, or are pending registration with the U.S. Patent and Trademark Office and with other countries. All other trademarks mentioned herein are used for identification purposes only and are trademarks (and may be registered trademarks) of their respective companies.

© 2021 N-able Solutions ULC and N-able Technologies Ltd. All rights reserved.

Karla Walls

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Networks Security Data Management Technology Software

MEDIA:

Logo
Logo

QIWI Announces 2021 Annual General Meeting

NICOSIA, Cyprus, April 19, 2021 (GLOBE NEWSWIRE) — QIWI plc (Nasdaq: QIWI), (MOEX: QIWI) (“QIWI” or the “Company”) today announced that its 2021 annual general meeting of shareholders (the “AGM”) will be held on Wednesday, June 2, 2021, at 10:00 a.m. (Cyprus time) at 12 Kennedy Avenue, Kennedy Business Centre, 2nd floor, 1087, Nicosia, Cyprus.

Only shareholders of record at the close of business on April 15, 2021 are entitled to receive notice and to vote at the AGM and any adjourned meeting thereof. Holders of the Company’s American Depositary Shares (the “ADS”) who wish to exercise their voting rights for the underlying shares must act through the depositary of the Company’s ADS program, The Bank of New York Mellon. Shareholders are cordially invited to attend the AGM.

At the AGM, the following items will be submitted for shareholders approval:

  1. to adopt the Company’s audited financial statements for 2020 financial year;
  2. to appoint EY as the Company’s Auditors and to fix Auditors’ remuneration;
  3. to elect Directors of the Board of Directors of the Company;
  4. to approve Directors’ remuneration, and
  5. to approve amended and restated Articles of Association of the Company.

Further details on the agenda and procedural matters related to the AGM will be made available to the Company’s shareholders by the Company and the Company’s ADS holders through The Bank of New York Mellon.

Copies of certain materials related to the AGM, including Notice for the convocation of the AGM, a marked up version of the Articles of Association, and Board of Directors Nomination Form are available on our website at http://investor.qiwi.com.

About QIWI plc.

QIWI is a leading provider of next generation payment and financial services in Russia and the CIS. It has an integrated proprietary network that enables payment services across online, mobile and physical channels. It has deployed over 18.1 million virtual wallets, over 113,000 kiosks and terminals, and enabled merchants and customers to accept and transfer over RUB 135 billion cash and electronic payments monthly connecting over 31 million consumers using its network at least once a month. QIWI’s consumers can use cash, stored value and other electronic payment methods in order to pay for goods and services or transfer money across virtual or physical environments interchangeably.



Contact
Investor Relations
+357.25028091
[email protected]

Spectrum Brands Holdings to Report Fiscal 2021 Second Quarter Financial Results and Hold Conference Call and Webcast on May 7, 2021

Spectrum Brands Holdings to Report Fiscal 2021 Second Quarter Financial Results and Hold Conference Call and Webcast on May 7, 2021

MIDDLETON, Wis.–(BUSINESS WIRE)–
Spectrum Brands Holdings, Inc. (NYSE: SPB; “Spectrum Brands” or the “Company”), a leading global branded consumer products and home essentials company focused on driving innovation and providing exceptional customer service, announced today it will release its fiscal 2021 second quarter financial results for the period ended April 4, 2021 before the markets open on Friday, May 7.

Spectrum Brands will conduct a live conference call and live webcast on May 7 at 9:00 a.m. Eastern Time (8:00 a.m. Central Time) which will be hosted by David Maura, Executive Chairman and Chief Executive Officer; Jeremy Smeltser, Executive Vice President and Chief Financial Officer; and Randy Lewis, Executive Vice President and Chief Operating Officer.

To access the live audio conference call, U.S. participants may call 877-604-7329 and international participants may call 602-563-8688. The conference call ID number is 5384608. A live webcast and related presentation slides will be available by visiting the Event Calendar page in the Investor Relations section of Spectrum Brands’ website at www.spectrumbrands.com.

Following the call, a replay of the live webcast also will be accessible through the Event Calendar page in the Investor Relations section of the Company’s website.

A telephone replay of the conference call will be available through Friday, May 21. To access this replay, all participants may call 855-859-2056 and use the conference call ID number provided above.

About Spectrum Brands Holdings, Inc.

Spectrum Brands Holdings, a member of the Russell 1000 Index, is a leading supplier of residential locksets, residential builders’ hardware, plumbing, shaving and grooming products, personal care products, small household appliances, specialty pet supplies, lawn and garden and home pest control products, and personal insect repellents. Helping to meet the needs of consumers worldwide, the Company offers a broad portfolio of market-leading, well-known and widely trusted brands including Kwikset®, Weiser®, Baldwin®, National Hardware®, Pfister®, Remington®, George Foreman®, Russell Hobbs®, Black+Decker®, Tetra®, Marineland®, Nature’s Miracle®, Dingo®, 8-in-1®, FURminator®, IAMS® and Eukanuba® (Europe only), Digest-eeze™, Healthy-Hide®, Littermaid®, Good Boy®, Meowee!® , Wildbird®, Wafcol®, OmegaOne®, OmegaSea®, Spectracide®, Cutter®, Repel®, Hot Shot®, Black Flag®, and Liquid Fence®. For more information, please visit www.spectrumbrands.com. Spectrum Brands – A Home Essentials Company™

Investor/Media Contact:

Kevin Kim

608-278-6148

KEYWORDS: Wisconsin United States North America

INDUSTRY KEYWORDS: Other Consumer Construction & Property Department Stores Other Retail Pets Interior Design Building Systems Home Goods Consumer Retail

MEDIA:

Logo
Logo

Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain

Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain

DURHAM, N.C.–(BUSINESS WIRE)–
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) (“Roclanda®”) has received marketing authorisation from the Medicines and Healthcare Products Regulatory Agency (“MHRA”) in Great Britain. Roclanda® is indicated for the reduction of elevated intraocular pressure (“IOP”) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction (reference Great Britain Summary of Product Characteristics).

Roclanda® was granted a marketing authorisation by the European Commission (“EC”) in January 2021 for the same indication. The EC marketing authorisation is valid in all 27 countries of the European Union, plus Iceland, Norway and Liechtenstein. Through the EC marketing authorisation, Roclanda® is also authorised in Northern Ireland. As the EC decision was received after the end of the Brexit transition period, Aerie was required to complete a further administrative step in order to obtain authorisation in Great Britain, which has now been granted.

“The authorisation of Roclanda® in Great Britain, the only fixed-dose combination IOP-lowering therapy with a prostaglandin analogue that does not include a beta blocker, is another important regulatory milestone for Aerie on the heels of the receipt of the EC marketing authorisation for Roclanda® in January,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie. “We continue to evaluate our potential collaboration opportunities in Europe and this authorisation is another important step in furthering those discussions.”

Roclanda® was authorised by the U.S. Food and Drug Administration in March 2019 under the trade name Rocklatan® for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, and instillation site pain. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “exploring,” “pursuing” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the duration and severity of the coronavirus disease (COVID-19) outbreak, including the impact on our clinical and commercial operations, demand for our products and financial results and condition of our global supply chains; our expectations regarding the commercialization and manufacturing of Rhopressa®, Rocklatan®, Rhokiinsa® and Roclanda® or any product candidates or future product candidates, including the timing, cost or other aspects of their commercial launch; our commercialization, marketing, manufacturing and supply management capabilities and strategies in and outside of the United States; the success, timing and cost of our ongoing and anticipated preclinical studies and clinical trials for Rhopressa® and Rocklatan®, with respect to regulatory authorisation outside of the United States, and any product candidates or future product candidates, including statements regarding the timing of initiation and completion of the studies and trials; our expectations regarding the effectiveness of Rhopressa®, Rocklatan®, Rhokiinsa®, Roclanda® or any product candidates or future product candidates; the timing of and our ability to request, obtain and maintain FDA or other regulatory authority authorisation of, or other action with respect to, as applicable, Rhopressa®, Rocklatan® or any product candidates, preclinical implants or future product candidates; the potential advantages of Rhopressa® and Rocklatan® or any product candidates or future product candidates; our plans to pursue development of additional product candidates and technologies; our plans to explore possible uses of our existing proprietary compounds beyond glaucoma, including development of our retina program; our ability to protect our proprietary technology and enforce our intellectual property rights or to develop new intellectual property; and our expectations regarding strategic operations, including our ability to in-license or acquire additional ophthalmic products, product candidates or technologies. In particular, FDA authorisation of Rhopressa® and Rocklatan®, European Medicines Agency (EMA) authorisation Rhokiinsa® and Roclanda® and MHRA authorisation of Roclanda® do not constitute regulatory authorisation of Rhopressa® and Rocklatan® in other jurisdictions, and there can be no assurance that we will receive regulatory authorisation for Rhopressa® and Rocklatan® in such other jurisdictions. In addition, FDA authorisation of Rhopressa® and Rocklatan® do not constitute FDA authorisation of our product candidates or any future product candidates, and there can be no assurance that we will receive FDA authorisation for our product candidates or any future product candidates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control, and depend on regulatory authorisations and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading “Risk Factors” in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Media: Tad Heitmann 949-526-8747; [email protected]

Investors: Ami Bavishi 908-947-3949; [email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: General Health Pharmaceutical Optical Health

MEDIA:

Logo
Logo

Kenon Holdings Reports Full Year 2020 Results and Additional Updates

Agreement to sell remaining 12% of Qoros; Cash dividend of $100 million

PR Newswire

SINGAPORE, April 19, 2021 /PRNewswire/ — Kenon Holdings Ltd. (NYSE: KEN) (TASE: KEN) (“Kenon“) announces its results for 2020 and updates to its businesses.


Recent Highlights

Qoros

  • Kenon’s subsidiary Quantum has entered into an agreement to sell all of its remaining 12% interest in Qoros for a total purchase price of RMB1.56 billion (approximately $238 million).

Kenon

  • In April 2021, Kenon’s board of directors approved an interim cash dividend of $1.86 per share (approximately $100 million in total) (the “Dividend“).
  • Kenon’s net profit in 2020 was $496 million, as compared to a net loss of $22 million in 2019.

ZIM

  • In February 2021, ZIM completed an initial public offering of its shares raising $204 million in net proceeds.
  • Financial results:
    • ZIM’s net profit in 2020 was $524 million, as compared to a net loss of $13 million in 2019.

OPC

  • In January 2021, OPC completed the acquisition of Competitive Power Ventures group (“CPV“).
  • Financial results:
    • OPC’s revenues in 2020 increased to $386 million, as compared to $373 million in 2019.
    • OPC’s net loss in 2020 was $13 million, as compared to net profit of $34 million in 2019 (including the negative impact of $12 million relating to non-recurring acquisition expenses in 2020 and $4 million relating to non-recurring revenue in 2019).
    • OPC’s EBITDA[1] in 2020 decreased to $75 million, as compared to $105 million in 2019.


Discussion of Results for the Year ended December 31, 2020

Kenon’s consolidated results of operations from its operating companies essentially comprise the consolidated results of OPC Energy Ltd (“OPC“). The results of Qoros Automotive Co., Ltd. (“Qoros“) (for four months until we reduced our stake in Qoros to 12% on April 29, 2020) and ZIM Integrated Shipping Ltd. (“ZIM“) are reflected under results from associates.

See Exhibit 99.2 of Kenon’s Form 6-K dated April 19, 2021 for summary Kenon consolidated financial information; summary OPC consolidated financial information; a reconciliation of OPC’s EBITDA (which is a non-IFRS measure) to net profit and summary operational information of each of OPC’s generation businesses.



OPC



 

The following discussion of OPC’s results of operations is derived from OPC’s consolidated financial statements, as translated into US dollars.

Summary Financial Information of OPC


2020


2019


$ millions

Revenue

386

373

Cost of sales (excluding depreciation and amortization)

282

256

Finance expenses, net

50

26

Net (loss)/profit

(13)

34

EBITDA1

75

105


Includes non-recurring acquisition expenses of $12 million in 2020, and non-recurring revenue of $4 million in 2019.

 

Revenue


For the year ended
December 31,


2020


2019


$ millions

Revenue from energy generated by OPC and sold to private customers

246

261

Revenue from energy purchased by OPC and sold to private customers

29

16

Revenue from private customers in respect of infrastructures services

80

76

Revenue from energy sold to the System Administrator

15

3

Revenue from sale of steam

16

17


Total


386


373

 

OPC’s revenue from the sale of electricity to private customers derives from electricity sold at the generation component tariffs, as published by the Israeli Electricity Authority (“EA”), with some discount. Accordingly, changes in the generation component tariffs generally affect the prices paid under PPAs by customers of OPC-Rotem and OPC-Hadera. The weighted-average generation component tariff for 2020, as published by the EA, was NIS 0.2678 per KW hour. In 2019, the weighted-average generation component tariff was approximately 8% higher at NIS 0.2909 per KW hour. OPC’s revenues from sale of steam are linked partly to the price of gas and partly to the Israeli Consumer Price Index.

Set forth below is a discussion of the changes in revenues by category between 2020 and 2019.

  • Revenue from energy generated by OPC and sold to private customers – decreased by $15 million in 2020, as compared to 2019. As OPC’s revenue is denominated in NIS, translation of its revenue into US Dollars had a positive impact of $10 million. Excluding the impact of exchange rate fluctuations, these revenues decreased by $25 million primarily as a result of (i) a $21 million decrease in revenues due to a decrease in the generation component tariff, (ii) a $14 million decrease due to maintenance of the OPC-Rotem power plant and (iii) a $4 million decrease due to lower consumption of OPC’s customers, partially offset by an $14 million increase in revenues due to the commercial operation of the OPC-Hadera power plant which started in July 2020.
  • Revenue from energy purchased by OPC and sold to private customers – increased by $13 million in 2020, as compared to 2019, primarily as a result of an increase in acquisition of energy for customers of the OPC-Hadera power plant and the OPC-Rotem power plant during maintenance periods for those plants.
  • Revenue from private customers in respect of infrastructure services – increased by $4 million in 2020, as compared to 2019. As OPC’s revenue is denominated in NIS, translation of its revenue into US Dollars had a positive impact of $3 million. Excluding the impact of exchange rate fluctuations, these revenues increased by $1 million primarily as a result of a $7 million increase due to the commercial operation of the OPC-Hadera power plant partially offset by (i) a $3 million decrease due to lower consumption of OPC-Rotem’s customers and (ii) a $3 million decrease in infrastructure tariffs.
  • Revenue from energy sold to the System Administrator – increased by $12 million in 2020, as compared to 2019, primarily as a result of increases in sale of energy by OPC-Rotem power plant and OPC-Hadera power plant to the System Administrator.

 

Cost of Sales (Excluding Depreciation and Amortization)


For the year ended
December 31,


2020


2019


$ millions

Natural gas and diesel oil consumption

135

138

Payment to IEC for infrastructure services and purchase of electricity

116

92

Natural gas transmission

10

9

Operating expenses

21

17


Total


282


256

 

  • Natural gas and diesel oil consumption – decreased by $3 million in 2020, as compared to 2019. As OPC’s cost of sales is denominated in NIS, translation of its cost of sales into US Dollars had a negative impact of $5 million. Excluding the impact of exchange rate fluctuations, OPC’s cost of sales decreased by $8 million primarily as a result of (i) a $12 million decrease in electricity generation due to maintenance and load reduction at the OPC-Rotem power plant and (ii) a $7 million decrease due to a decrease in the gas price as a result of the drop in generation component and USD-NIS exchange rate fluctuations, partially offset by an $11 million increase in gas expenses due to the commencement of commercial operations of the OPC-Hadera power plant.
  • Payment to IEC for infrastructures services and purchase of electricity – increased by $24 million in 2020, as compared to 2019. As OPC’s cost of sales is denominated in NIS, translation of its cost of sales into US Dollars had a negative impact of $4 million. Excluding the impact of exchange rate fluctuations, OPC’s cost of sales increased by $20 million primarily as a result of (i) a $13 million increase due to the commencement of commercial operation of the OPC-Hadera power plant and start of sales to customers and (ii) a $10 million increase due to an increase in acquisition of energy as a result of maintenance and corresponding load reductions on the OPC-Rotem power plant, partially offset by a $3 million decrease due to a decline in infrastructure tariffs.

Finance Expenses, net 

Finance expenses, net increased by approximately $24 million in 2020 as compared to 2019, primarily as a result of (i) a $12 million one-off expense due to early repayment of Series A debentures, (ii) a $6 million increase as a result of commercial operation of the OPC-Hadera power plant and the related discontinuance of capitalisation of financing expenses, and (iii) a $5 million increase as a result of US Dollar – Israeli Shekel exchange rate fluctuations.

Liquidity and Capital Resources

As of December 31, 2020, OPC had cash and cash equivalents and short-term deposits of $562 million, debt service reserves (out of restricted cash) of $46 million, and total outstanding consolidated indebtedness of $921 million, consisting of $49 million of short-term indebtedness and $872 million of long-term indebtedness. All of OPC’s debt at December 31, 2020 was denominated in NIS.

Recent Business Developments


CPV transaction

On January 25, 2021, OPC announced that it has completed the acquisition of CPV. The details of the acquisition are discussed in more detail in Kenon’s Form 6-K dated January 24, 2021.


Private Placement

In January 2021, OPC issued 10,300,000 new shares in a private placement for a purchase price of approximately $107 million, at a per share price of NIS 34.0. The issuance of the shares resulted in Kenon’s stake in OPC being diluted to 58.6%.


Update on Tzomet Project

Tzomet Energy Ltd. (“Tzomet”) is developing an open-cycle natural gas-fired power station with capacity of approximately 396 MW in Israel. OPC expects that the total cost of completing the Tzomet project will be approximately NIS 1-1.5 billion (approximately $0.3-0.5 billion). Construction of the Tzomet project began in 2020, and is expected to reach commercial operation in January 2023. As of December 31, 2020, OPC had invested an aggregate of NIS 694 million (approximately $216 million) in the project.



ZIM


IPO

In February 2021, ZIM successfully completed an initial public offering of its shares raising $204 million in net proceeds. The issuance of shares in the IPO resulted in Kenon’s stake being diluted to 27.8%.


Discussion of ZIM’s Results for 2020

For the year ended December 31, 2020, ZIM’s net profit was $524 million, as compared to a loss of $13 million in 2019.

ZIM carried approximately 2,841 thousand TEUs in 2020 representing a 0.7% increase as compared to 2019, in which ZIM carried approximately 2,821 thousand TEUs. The average freight rate per TEU in 2020 was $1,229 per TEU, as compared to $1,009 per TEU in 2019.

ZIM’s revenues increased by 21.0% in 2020 to approximately $4.0 billion, as compared to approximately $3.3 billion in 2019, primarily due to (i) an increase of $645 million in revenues from containerized cargo due to an increase in average freight rate, (ii) an increase of $33 million in income from related services, and (iii) an increase of $22 million in income from slots and chartered vessels.

ZIM’s operating expenses and cost of services increased by 0.9% to approximately $2.84 billion, as compared to approximately $2.81 billion in 2019, primarily due to (i) an increase in expenses of related service and sundry of $39 million, (ii) an increase in cargo handling expenses of $12 million, offset by (iii) a decrease in bunker expenses of $25 million.



Qoros



 

Kenon’s subsidiary Quantum (2007) LLC (“Quantum“) has entered into an agreement with the China-based investor related to the Baoneng Group that holds 63% of Qoros (the “Majority Shareholder in Qoros“) to sell all of its remaining 12% interest in Qoros. The key terms of the agreement are set forth below.

The total purchase price is RMB1.56 billion (approximately $238 million), which is the same valuation as the previous sales by Quantum to the Majority Shareholder in Qoros. The deal is subject to certain conditions, including a release of the share pledge over the shares to be sold (substantially all of which have been pledged to Qoros’ lending banks), approval of the transaction by the National Development and Reform Commission and registration with the State Administration of Market Regulation.

An entity within the Baoneng Group has guaranteed the obligations of the Majority Shareholder in Qoros under this agreement.

The purchase price is to be paid over time pursuant to the following schedule:

 


Installment


Amount


(RMB)


Percentage of the
Aggregate Purchase
Price


Payment Date

Deposit

78,000,000

5%

July 31, 2021, or
earlier if certain
conditions are met1

First Payment

312,000,000

20%

September 30, 20211

Second Payment

390,000,000

25%

March 31, 20221

Third Payment

390,000,000

25%

September 30, 2022

Fourth Payment

390,000,000

25%

March 31, 2023


1 Payments to a designated account.

 

The first and second payments, including the deposit, will be paid into a designated account set up in the name of the Majority Shareholder in Qoros over which Quantum has joint control. According to the agreement, the transfer of these payments to Quantum will occur by the end of Q2 2022, provided that the relevant conditions are met in connection with the registration of the shares to the purchaser subject to receipt by Quantum of collateral acceptable to it. The agreement provides that the third and fourth payments will be paid directly to Quantum.


Car Sales

Qoros sold approximately 12,600 cars in 2020 as compared to approximately 26,000 cars in 2019. Qoros sold approximately 700 cars in Q1 2021 as compared to approximately 500 cars in Q1 2020.



Additional Kenon Updates


Kenon’s (Unconsolidated) Liquidity and Capital Resources

As of December 31, 2020, Kenon’s unconsolidated cash balance was $222 million. Following the payment of a dividend as described below, Kenon’s unconsolidated cash balance will be approximately $122 million. There is no material debt at the Kenon level.


Interim dividend for the year ending December 31, 2021

In April 2021, Kenon’s board of directors approved an interim cash dividend of $1.86 per share (an aggregate amount of approximately $100 million) relating to the year ending December 31, 2021, payable to Kenon’s shareholders of record as of the close of trading on April 29, 2021 (the “Record Date“), to be paid on or about May 6, 2021 (the “Payment Date“).

In November 2020, Kenon paid a dividend of approximately $120 million ($2.23 per share).

These dividends are consistent with Kenon’s strategy of realizing the value of its businesses for its shareholders.

The New York Stock Exchange’s (the “NYSE“) ex-dividend date, which is the date on which Kenon’s shares will begin trading on the NYSE without the entitlement to the Dividend, is April 28, 2021 (the “NYSE Ex-Dividend Date“). The NYSE will adjust the price of Kenon’s shares on the NYSE Ex-Dividend Date to reflect the Dividend.

The Tel Aviv Stock Exchange’s (“TASE“) ex-dividend date, which is the date on which Kenon’s shares will begin trading on the TASE without the entitlement to the Dividend, is April 29, 2021 (the “TASE Ex-Dividend Date“). The TASE will adjust the price of Kenon’s shares on the TASE Ex-Dividend Date to reflect the Dividend.

We encourage you to contact your bank, broker, nominee or other institution if you have any questions regarding the mechanics and timing of having the Dividend attributable to your shares credited to your account.

Singapore tax is not expected to be imposed on Kenon’s shareholders in connection with the Dividend. Nevertheless, the Dividend may constitute a taxable event to Kenon’s shareholders according to their jurisdiction and the relevant tax law applicable (including for the purpose of withholding tax in accordance with applicable law and/or regulation). Kenon’s shareholders should consult their tax advisors with respect to the federal, state, and/or any other applicable tax consequences of the Dividend, and the potential imposition of withholding taxes in connection with the Dividend.


About Kenon

Kenon is a holding company that operates dynamic, primarily growth-oriented businesses. The companies it owns, in whole or in part, are at various stages of development:

  • OPC (58% interest) – a leading owner, developer and operator of power generation facilities in the Israeli and US power markets;
  • ZIM (28% interest) – an international shipping company; and
  • Qoros (12% interest[2]) – a China-based automotive company.

For further information on Kenon’s businesses and strategy, see Kenon’s publicly available filings, which can be found on the SEC’s website at www.sec.gov. Please also see http://www.kenon-holdings.com for additional information.


[1] EBITDA is a non-IFRS measure. See Exhibit 99.2 of Kenon’s Form 6-K dated April 19, 2021 for the definition of OPC’s EBITDA and a reconciliation to its net profit for the applicable period.

[2] Kenon has agreed to sell its remaining 12% interest to the majority shareholder in Qoros; upon completion of this sale, Kenon will no longer be a shareholder of Qoros.


Caution Concerning Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to,
statements relating to Kenon’s subsidiary Quantum’s agreement to sell its remaining interest in Qoros and related statements, including statements relating to the terms of the transaction, the timing for payments and transfer of shares and conditions to the parties’ obligations,
 statements
about the Dividend, including the Payment Date, the Record Date, the NYSE Ex-Dividend Date, the TASE Ex-Dividend Date, the crediting of accounts with the Dividend, the amount of cash to be retained by
Kenon following the Dividend and statements about the expected Singapore tax treatment of the Dividend
, as well as statements relating to the Tzomet project, including expected installed capacity and expected cost and timing for completion of the project, and other non-historical matters. These statements are based on current expectations or beliefs and are subject to uncertainty and changes in circumstances. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond Kenon’s control, which could cause the actual results to differ materially from those indicated in such forward-looking statements. Such risks include risks relating to
completion of the transaction, including risks relating to meeting the conditions to the obligations under the transaction including risks relating to regulatory approvals and the condition that the pledge over the shares to be sold be released, and risks relating to the payments to be made to Quantum and released from the designated account and the timing thereof and risks related to the
payment of the Dividend and that the amounts retained by
Kenon are not sufficient to meet its cash needs, statements relating to the expected tax treatment of the Dividend in Singapore,
 potential failure to complete the development and reach commercial operation of the Tzomet project as described or at all, including risks related to costs associated with delays or higher costs in reaching commercial operation and other risks and factors
including
 those risks set forth under the heading “Risk Factors” in Kenon’s Annual Report on Form 20-F filed with the SEC and other filings. Except as required by law, Kenon undertakes no obligation to update these forward-looking statements, whether as a result of new information, future events, or otherwise.


Contact Info


Kenon Holdings Ltd.


Mark Hasson

Chief Financial Officer


[email protected]

Tel: +65 9726 8628

 

Cision View original content:http://www.prnewswire.com/news-releases/kenon-holdings-reports-full-year-2020-results-and-additional-updates-301271392.html

SOURCE Kenon Holdings Ltd.

Canadian team one of two to win $20-million global tech competition

NRG COSIA Carbon XPRIZE proves recycling carbon emissions into products is a viable solution to help address climate change

Calgary, AB, Canada, April 19, 2021 (GLOBE NEWSWIRE) — Calgary, AB, Canada – A Nova Scotia clean technology company has won the international NRG COSIA Carbon XPRIZE competition, a feat that’s also a win for Canada’s emerging carbon economy. Dartmouth-based CarbonCure Technologies shares the top prize with California-based UCLA CarbonBuilt, with the teams competing in natural gas and coal tracks respectively. The two winners from a cohort of 10 finalists demonstrated they could convert the most carbon dioxide (CO) into the highest value products. Each takes home a grand prize of US$7.5 million, in addition to $500,000 awarded to each finalist earlier in the competition.

Canada’s Oil Sands Innovation Alliance (COSIA) co-sponsored the multi-year competition through a joint industry project led by COSIA member ConocoPhillips Canada, supported by other members Canadian Natural, Cenovus Energy, Imperial, Suncor and non-member CNOOC. Together, COSIA members represent 90 per cent of oil sands production and through COSIA, collaborate on clean technology innovation to improve the environmental performance of Canada’s oil sands.

“The NRG COSIA Carbon XPRIZE has proven that converting CO2 into everyday products can be a game-changing pathway in our broader efforts to reduce emissions. Through breakthrough technologies, we can tackle the major causes of climate change, create new economic opportunities and build a bridge to a cleaner, abundant and affordable energy future,” says Wes Jickling, COSIA’s Chief Executive. “We congratulate the teams and winners and are very proud of what’s been achieved. This is a shining example of the collaboration that’s required across industries and borders to address climate change, while meeting global energy needs.”  

Teams in the competition, administered by the US-based XPRIZE Foundation, have advanced technologies that can address climate change by converting CO2 emissions into products like environmentally friendly concrete, plastics and even vodka. Both winning teams are recycling CO2 emissions into concrete related products – one of the most abundantly used materials on earth.

“The prize helped to develop tangible innovation in CO2 conversion and carbon tech, and that is thanks to the hard work of the teams, and the support of NRG and COSIA, especially the test centers created to make this prize possible,” said Marcius Extavour, XPRIZE Vice President of Energy and Climate. “Some of the solutions are already in the market, and others are ready to be deployed. It’s time to act in decarbonization, and the solutions showcased during the prize represent a path forward.”

Jickling says, “supporting this initiative is just one example of work underway in Canada’s oil sands to improve environmental performance. In fact, Canada’s oil and natural gas companies spend more on clean technology investments than all other industries combined, with 75% of the $1.4 billion invested annually in Canada coming from our oil and natural gas industry.”

The XPRIZE competition is also an important step forward in progressing Canada’s carbon economy, which has considerable potential to become a new commercial industry including through making products from C02. By elevating the profile of carbon capture and utilization technologies, the competition brought together some of the leading innovators working in this space and is estimated to have attracted an additional US$150 million in outside funding for participants, including from Bill Gates, Amazon and Shopify.

Globally, the carbon capture and utilization sector is thought to be a $6 trillion opportunity, with the potential to spur new industries and products that could transform our world by slowing climate change. Many experts believe that Canada has the potential to be a leader in this area.

An important legacy of the competition is the Calgary-based Alberta Carbon Conversion Technology Centre (ACCTC), a testing facility that was purpose built for Carbon XPRIZE competitors in the natural gas track. It is now open to innovators from anywhere in the world looking to advance carbon capture and utilization technologies. The ACCTC is poised to be a global hub for groundbreaking innovation that addresses the climate-related risks of excess CO2 emissions while creating new economic opportunities.

“Alberta is at the forefront of carbon capture and utilization research thanks to the Alberta Carbon Conversion Technology Centre and all the competitors in the NRG COSIA Carbon XPRIZE. The ACCTC provides the platform for innovators and entrepreneurs to de-risk the development process and move their technology forward to commercial success, thanks to the unique facilities and expertise of our subsidiary, InnoTech Alberta.” says Laura Kilcrease, CEO of Alberta Innovates, which owns and operates the ACCTC.

 

Find out more about the NRG COSIA Carbon XPRIZE at transformingthefuture.ca.

 

About COSIA:

Canada’s Oil Sands Innovation Alliance (COSIA) is a unique alliance of oil sands producers focused on accelerating environmental performance in Canada’s oil sands. COSIA enables collaboration and innovation between thinkers from industry, government, academia and the wider public to improve measurement, accountability and performance in the oil sands across our environmental priority areas of greenhouse gases, land, water and tailings. COSIA members search the world for solutions to our toughest problems. And we have some of the best minds on the planet working on technologies to enable further responsible and sustainable development.

Visit COSIA at www.cosia.ca. Follow us on LinkedIn, Facebook and Twitter.

 

About XPRIZE:

XPRIZE is a global future-positive movement of over 1M people and rising, delivering truly radical breakthroughs for the benefit of humanity. XPRIZE inspires and empowers a global community of problem-solvers to positively impact our world by crowdsourcing solutions through large-scale competitions, tackling the world’s grandest challenges in exploration, environment and human equity. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, $10 Million XPRIZE Rainforest, $15 Million XPRIZE Feed the Next Billion, $10 Million ANA Avatar XPRIZE, $6 Million XPRIZE Rapid COVID Testing, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling, $1 Million XPRIZE Next-Gen Mask Challenge and $500,000 Pandemic Response Challenge. Donate, sign up or join a team at xprize.org.

-30-

Media Contacts:

COSIA

Rob Gray
Tel: 403-880-3536
E-mail: [email protected]

XPRIZE

Caden Kinard
Tel: 949-280-0182
E-mail: [email protected]


CarbonCure

Pal Hollywood, Sterling Communications
Tel: 408-355-9880
E-mail: [email protected]

 

Alberta Innovates

Dwayne Brunner
Tel: 587-572-4091
E-mail: [email protected]

Attachments



Rob Gray, Director, Communications & Outreach
Canada's Oil Sands Innovation Alliance (COSIA)
403.880.3536
[email protected]

CytoDyn Submits First and Most Crucial Section (CMC) of Interim Order Application to Health Canada for COVID-19 Under Rolling Review

Clinical trial in U.S. for critically ill COVID-19 patients expected to initiate soon

CytoDyn in discussions with Brazil to initiate two COVID-19 trials, one for severe and one for critically ill patients

VANCOUVER, Washington, April 19, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today it has submitted the manufacturing section (CMC) of the application for an Interim Order to Health Canada under a rolling review. This crucial part of the application documents the Company’s manufacturing (CMC) practices are in full compliance with GMP requirements. The Company anticipates the remaining sections will be submitted in the very near future.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “Our entire regulatory team has been working non-stop to complete the submission of the manufacturing section of the Interim Order to Health Canada for leronlimab to be considered as a therapeutic for COVID-19. Our clinical team is working on initiating three trials in parallel. In Brazil, two clinical trial protocols for COVID-19 will be submitted to ANVISA, the Brazilian regulatory authority. In the U.S., we will soon finalize a COVID-19 trial protocol to potentially include a dosage regimen utilizing IV (intravenous) as the first dose and three subcutaneous doses thereafter. We are moving quickly to advance leronlimab along multiple regulatory paths, including securing additional manufacturing from Samsung BioLogics in 2021 and 2022.”

About Leronlimab (PRO 140)

The U.S. Food and Drug Administration (FDA) granted CytoDyn Fast Track designation to explore two potential indications using leronlimab to treat HIV and metastatic cancer. The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC). Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor important in HIV infection, tumor metastases, and other diseases, including NASH (nonalcoholic steatohepatitis). Leronlimab has been studied in 11 clinical trials involving more than 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients). 

Leronlimab is a viral-entry inhibitor in HIV/AIDS. It masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent with fewer side effects and less frequent dosing requirements than currently used daily drug therapies. 

Cancer research has shown CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. As a result, CytoDyn is conducting two Phase 2 human clinical trials, one in mTNBC, which was granted Fast Track designation by the FDA in 2019, and a second in a basket trial which encompasses 22 different solid tumor cancers.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. After completing two clinical trials with COVID-19 patients (a Phase 2 and a Phase 3), CytoDyn initiated a Phase 2 investigative trial for post-acute sequelae of SARS COV-2 (PASC), also known as COVID-19 Long-Haulers. This trial will evaluate the effect of leronlimab on clinical symptoms and laboratory biomarkers to further understand the pathophysiology of PASC. It is currently estimated that between 10-30% of those infected with COVID-19 develop long-term sequelae. Common symptoms include fatigue, cognitive impairment, sleep disorders, and shortness of breath. If this trial is successful, CytoDyn plans to pursue clinical trials to evaluate leronlimab’s effect on immunological dysregulation in other post-viral syndromes, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

CytoDyn is also conducting a Phase 2 clinical trial for NASH to evaluate the effect of leronlimab on liver steatosis and fibrosis. Preclinical studies revealed a significant reduction in NAFLD and a reduction in liver fibrosis using leronlimab. There are currently no FDA approved treatments for NASH. NASH is a leading cause of liver transplant. About 30 to 40 percent of adults in the U.S. live with NAFLD, and 3 to 12 percent of adults in the U.S. live with NASH.

About CytoDyn

CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.

CytoDyn has successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn has been working diligently to refile its Biologics License Application (“BLA”) for this HIV combination therapy since receiving a Refusal to File in July 2020 and subsequently meeting with the FDA telephonically to address their written guidance concerning the filing. CytoDyn expects to refile its BLA in the first half of the calendar year 2021 or shortly thereafter.

CytoDyn also completed a Phase 3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension approval. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce the viral burden in people infected with HIV. Moreover, a Phase 2 clinical trial demonstrated that leronlimab monotherapy could prevent viral escape in HIV-infected patients; several patients on leronlimab’s Phase 2 monotherapy extension arm have remained virally suppressed for more than six years. There have been no strong safety signals identified in patients administered leronlimab in multiple disease spectrums, including patients with HIV, COVID-19 and Oncology.

CytoDyn is also conducting a Phase 2 clinical trial with leronlimab in mTNBC, a Phase 2 basket trial in solid tumor cancers (22 different cancer indications), Phase 2 investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 Long-Haulers, and a Phase 2 clinical trial for NASH. CytoDyn has already completed two trial in COVID-19 patients (a Phase 2 and a Phase 3) and is in the process of conducting an additional COVID-19 Phase 3 trial for mechanically ventilated critically ill COVID-19 patients. More information is at www.cytodyn.com

Forward-Looking Statements 

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to provide positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTS

Investors:

Michael Mulholland
Office: 360.980.8524, ext. 102
[email protected]



Petco Urges Employers Not to Forget Fido in “Return to Work” Plans, Will Introduce a New Playbook and Toolkit to Help Employers Go Pet-Friendly

In recognition of sixth annual National Pets at Work Day, Petco reveals new survey results that show pet parents are stressed about returning to work without their pets

PR Newswire

SAN DIEGO, April 19, 2021 /PRNewswire/ — As businesses across America develop and start to implement return-to-work plans, Petco Health and Wellness Company, Inc. (NASDAQ: WOOF), a complete partner in pet health and wellness, is urging employers to consider adopting a pet-friendly workplace policy among other post-pandemic changes and sharing information and resources for employees and employers ready to welcome pets at work.

The company will introduce a new playbook and toolkit this summer to help employers transition their workplace into a safe, healthy and productive environment for both people and pets. Offerings will include options ranging from DIY solutions for creating a pet-friendly workplace to benefits like pet insurance, Vital Care, on-site pet services and supplies.

“At Petco, we’ve experienced the benefits of working with and around pets all day for decades – whether in our Petco Pet Care Centers or our pet-friendly support center offices,” said Ron Coughlin, Petco’s Chairman and CEO. “The past year of quarantining and working from home has brought more pets into American families than ever before and significantly deepened the bonds we share with them. We want to see those bonds continue and ensure these pets remain an integral part of our families well into the future. As pet parents consider heading back to offices, we believe they will and should expect their employers to welcome their pets as well – and Petco is here to help companies do it.”

More than 3 million incremental new pets have entered U.S. homes in the past year,* and many of them have rarely, if ever, been separated from their humans for more than a few minutes or by more than one door in the house. Older family pets have long forgotten their old routines and become used to their two-legged family members being home most of if not all day long. Now, after more than a year of working from home – often with pets, children and other family members in tow – Petco’s latest survey** shows that 69% of pet parents are stressed about what returning to work means for their pets, and hopeful their employers may add “pet-friendly” to the list of post-pandemic office perks.

Other key findings from the survey include:

  • 44% of pet parents want their employers to adopt a pet-friendly workplace, and 41% would consider switching jobs if it meant they could bring their pet to work.
  • 83% of pet parents had minimized stress levels due to working from home in close contact with their furry friends.
  • 62% of pet parents have a more positive attitude toward companies that allow pets at work. If an employer had a pet-friendly policy:
    • 58% believe it would help alleviate stress while at work.
    • 52% would be likely to stay at their employer longer.
    • 47% believe it would promote better work productivity
  • Pet parents’ top three worries about returning to the workplace are their pet’s loneliness, their pet’s separation anxiety, and missing the comfort and joy experienced with having their pet with them while working.
  • 65% of pet parents who cannot bring their pets with them to the office worry about their pet’s separation anxiety, and 56% are concerned about leaving the pet at home all day without supervision or exercise.

Research shows that having a pet, or even interacting with one, has positive effects on both animals and people, which supports three of the five pillars – physical, mental and social health – of Petco’s Whole Health philosophy. The presence of friendly animals can reduce people’s heart rate, blood pressure and cholesterol; and regularly interacting with animals can reduce anxiety and promote calmness. Pets in the workplace can even enhance productivity, employee engagement and socialization among co-workers. Particularly given the concerns around post-pandemic separation anxiety and its impact on pet mental health, allowing pets into the office is also beneficial for pets’ mental well-being and will help ease the return to work transition.

“It’s no secret that pets come with a multitude of benefits for humans, from reducing stress to improving health,” said Dr. Whitney Miller, Chief Veterinarian at Petco. “Pets encourage us to stay active and provide incredible companionship, especially over the past year, when so many people have felt isolated at home and bereft of social interaction. When it comes to pets in the workplace, I’m confident that as more companies witness the positive effects that pets have on employees and company culture, the more they’ll see enhanced overall morale, which bodes well for business performance.”

As a leading pet-friendly employer, Petco can offer expertise for how other companies can foster and manage pet-friendly office environments, and keep both pets and people safe, comfortable and happy. With employers already making changes in their office spaces and flexible work policies, Petco invites other companies to include pets in the conversation around shifts in the workplace and offer employees the flexibility to bring their pets to work.

Petco’s recommended set of pet-friendly workplace guidelines and etiquette includes:

  • Creating a thorough policy for bringing pets to work that includes requiring up-to-date pet vaccinations, an action plan for any pet-related incidents and clear requirements for pet housing, such as pet gates, small animal habitats and aquariums.
  • Ensuring there are readily accessible outdoor areas for pet breaks.
  • Investing in built-in or removable pet gates at employee workspaces to make containment safe and easy.
  • Designating pet-free zones for employees who have allergies.
  • Clearing any pet-zone areas of potentially dangerous items such as cables, human food or furniture that could easily be knocked down.
  • Providing pet clean-up stations, offering things like stain and odor eliminator spray and deodorizing wipes, for inevitable “accidents” around the office.

Petco established National Pets at Work Day in 2016 to lead the charge in raising awareness for the mental, social and business health benefits associated with having pets in the workplace for pets, people and employers alike. Today, Petco is using #PetsAtWork to call on pet parents to share how bringing pets to the office would support their happiness in returning to work, and asking business owners, HR leaders and office space landlords to share the benefits they’ve experienced by going pet-friendly or what they would need to make the switch.

Petco provides pet parents with unique benefits aimed at supporting them throughout pet parenthood, including Petco Insurance, which offers accident and illness coverage for dogs and cats, as well as a pet bereavement policy that affords partners appropriate time to grieve when they lose a beloved pet. Additionally, Petco’s in-store and online dog training covers a variety of topics from potty and crate training to managing undesirable behaviors and helping with separation anxiety.

For more information on National Pets at Work Day, the benefits of pet-friendly workplaces and key tips for employers thinking about how to go pet-friendly, visit petco.com/petsatwork. Employers interested in learning more can reach out to [email protected].

*Source: Packaged Facts with adjustments from company internal estimates. 

**Statistics from 2021 Petco consumer survey of 2,001 U.S. pet parents.

About Petco, The Health + Wellness Co.

Petco is a category-defining health and wellness company focused on improving the lives of pets, pet parents and our own Petco partners. Since our founding in 1965, we’ve been trailblazing new standards in pet care, delivering comprehensive wellness solutions through our products and services, and creating communities that deepen the pet-pet parent bond. We operate more than 1,500 Petco locations across the U.S., Mexico and Puerto Rico, including a growing network of more than 100 in-store veterinary hospitals, and offer a complete online resource for pet health and wellness at petco.com and on the Petco app. In tandem with Petco Love (formerly the Petco Foundation), an independent nonprofit organization, we work with and support thousands of local animal welfare groups across the country and, through in-store adoption events, we’ve helped find homes for more than 6.5 million animals.

Contact:

Yvonne Tarrab

[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/petco-urges-employers-not-to-forget-fido-in-return-to-work-plans-will-introduce-a-new-playbook-and-toolkit-to-help-employers-go-pet-friendly-301270903.html

SOURCE Petco Health and Wellness Company, Inc.

BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update

PR Newswire

NEW YORK, April 19, 2021 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on April 26, 2021.

 

BrainStorm Logo

 

BrainStorm’s Chief Executive Officer, Chaim Lebovits, will present a corporate update after which participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, President and Chief Medical Officer, Stacy Lindborg, PhD, Executive Vice President and Global Head of Clinical Research, David Setboun, PharmD, MBA, Executive Vice President and Chief Operating Officer, Preetam Shah, PhD, MBA, Executive Vice President and Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: [email protected]. Questions should be submitted by 5:00 p.m. Eastern Time, Sunday, April 25, 2021.

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:

Toll Free:                                    877-407-9205
International:                              201-689-8054 
Webcast URL:                            https://www.webcaster4.com/Webcast/Page/2354/40513

Those interested in listening to the conference call live via the internet may do so by visiting the “Investors & Media” page of BrainStorm’s website at https://ir.brainstorm-cell.com/overview and clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Replay Numbers:

Toll Free:                                    877-481-4010
International:                              919-882-2331 
Replay Passcode:                      40513 

About NurOwn® 
The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS).

For more information, visit the company’s website at www.brainstorm-cell.com.

Contacts
Investor Relations:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Phone: +1 646-465-1138
[email protected]

Media:

Paul Tyahla

SmithSolve
Phone: + 1 973-713-3768
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/brainstorm-to-announce-first-quarter-financial-results-and-provide-a-corporate-update-301271353.html

SOURCE Brainstorm Cell Therapeutics Inc

X Financial Postpones Release of Fourth Quarter and Fiscal Year 2020 Financial Results to April 23, 2021

PR Newswire

SHENZHEN, China, April 19, 2021 /PRNewswire/ — X Financial (NYSE: XYF) (the “Company”), a leading technology-driven personal finance company in China, today announced that it is postponing the release of its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2020, toApril 23, 2021, after market closes.

X Financial’s management team will host an earnings conference call at 7:00 AM U.S. Eastern Time on Monday, April 26, 2021 (7:00 PM Beijing / Hong Kong Time on the same day).

Dial-in details for the earnings conference call are as follows:

United States:

1-888-346-8982

Hong Kong:

852-301-84992


Mainland China:

4001-201203

International:

1-412-902-4272

Passcode:

X Financial

Please dial in ten minutes before the call is scheduled to begin and provide the passcode to join the call.

A replay of the conference call may be accessed by phone at the following numbers until May 3, 2021:

United States:

1-877-344-7529

International:

1-412-317-0088

Passcode:

10154438

Additionally, a live and archived webcast of the conference call will be available at http://ir.xiaoyinggroup.com.

About X Financial

X Financial (NYSE: XYF) (the “Company”) is a leading online personal finance company in China. The Company is committed to connecting borrowers on its platform with its institutional funding partners. With its proprietary big data-driven technology, the Company has established strategic partnerships with financial institutions across multiple areas of its business operations, enabling it to facilitating loans to prime borrowers under a robust risk assessment and control system.

For more information, please visit: http://ir.xiaoyinggroup.com.

For more information, please contact:

X Financial
Mr. Frank Fuya Zheng
E-mail: [email protected]

Christensen

In China
Mr. Eric Yuan
Phone: +86-10-5900-1548
E-mail: [email protected]

In US 
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/x-financial-postpones-release-of-fourth-quarter-and-fiscal-year-2020-financial-results-to-april-23-2021-301271144.html

SOURCE X Financial